

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM832161

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Andelyn Biosciences, Inc.		08/14/2023	Corporation: OHIO
RECEIVING PARTY DATA			
Name:	Alter Domus (US) LLC, as Collateral Agent		
Street Address:	225 W. Washington St., 9th Floor		
Internal Address:	Attn: Legal Dept.		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60606		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	7083888	ANDELYN BIOSCIENCES	
Registration Number:	7014451	DIGITAL CDMO	
Registration Number:	7084156	PIONEERING SOLUTIONS THAT TURN HOPE INTO	
CORRESPONDENCE DATA			
Fax Number:	2134432926		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	213-617-5493		
Email:	jcravitz@sheppardmullin.com		
Correspondent Name:	SHEPPARD, MULLIN, RICHTER & HAMPTON LLP		
Address Line 1:	333 S. HOPE ST., 43RD FLOOR		
Address Line 2:	ATTN: J. CRAVITZ		
Address Line 4:	LOS ANGELES, CALIFORNIA 90071		
ATTORNEY DOCKET NUMBER:	76JM-327166		
NAME OF SUBMITTER:	Julie Cravitz		
SIGNATURE:	/julie cravitz/		
DATE SIGNED:	08/15/2023		
Total Attachments: 6			

CH \$90.00 7083888

source=First Supplemental Trademark Security Agreement#page1.tif
source=First Supplemental Trademark Security Agreement#page2.tif
source=First Supplemental Trademark Security Agreement#page3.tif
source=First Supplemental Trademark Security Agreement#page4.tif
source=First Supplemental Trademark Security Agreement#page5.tif
source=First Supplemental Trademark Security Agreement#page6.tif

FIRST SUPPLEMENTAL TRADEMARK SECURITY AGREEMENT

This **FIRST SUPPLEMENTAL TRADEMARK SECURITY AGREEMENT**, dated as of August 14, 2023 (this "Agreement"), is made by each of the signatories hereto indicated as a Grantor (each a "Grantor" and collectively, the "Grantors") in favor of ALTER DOMUS (US) LLC, a Delaware limited liability company, as Collateral Agent for the Secured Parties (in such capacity and together with its successors and assigns in such capacity, the "Collateral Agent").

WHEREAS, pursuant to that certain Credit Agreement dated as of March 18, 2021 by and among ANDELYN BIOSCIENCES, INC., an Ohio corporation (the "Borrower"), the several financial institutions or other entities from time to time parties thereto (the "Lenders") and ALTER DOMUS (US) LLC, a Delaware limited liability company, as disbursing agent for the Lenders and as collateral agent for the Secured Parties, and the other parties from time to time party thereto (as amended pursuant to that certain First Amendment to Credit Agreement dated as of November 4, 2022, that certain Second Amendment to Credit Agreement dated as of December 30, 2022, as further modified by that certain Waiver and Consent dated as of March 30, 2023, that certain Third Amendment to Credit Agreement dated as of June 23, 2023, that certain Fourth Amendment to Credit Agreement dated as of July 24, 2023, and that certain Consent and Fifth Amendment to Credit Agreement dated as of August 14, 2023, and as it may be further amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), the Lenders have severally agreed to make extensions of credit to the Borrower upon the terms and conditions set forth therein;

WHEREAS, as a condition precedent to the obligation of the Lenders to make their respective extension of credit to the Borrower under the Credit Agreement, the Grantors entered into a Guarantee and Collateral Agreement dated as of March 18, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the "Guarantee and Collateral Agreement") among each of the Grantors and the Collateral Agent, pursuant to which each of the Grantors assigned, transferred and granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in the Trademark Collateral (as defined below); and

WHEREAS, pursuant to the Guarantee and Collateral Agreement, each Grantor agreed to execute this Agreement, in order to record the security interest granted to the Collateral Agent for the benefit of the Secured Parties with the United States Patent and Trademark Office.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

SECTION 1. Defined Terms

Capitalized terms used but not defined herein shall have the respective meanings given thereto in the Guarantee and Collateral Agreement, and if not defined therein, shall have the respective meanings given thereto in the Credit Agreement.

SECTION 2. Grant of Security Interest in Trademark Collateral

SECTION 2.1 Grant of Security. Each Grantor hereby assigns and transfers to the Collateral Agent, and hereby grants to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, all of the following property, in each case, wherever located and now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time

in the future may acquire any right, title or interest (collectively, the “Trademark Collateral”) as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of such Grantor’s Obligations:

(a) all domestic, foreign and multinational trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, trade dress, trade styles, logos, Internet domain names, other indicia of origin or source identification, and general intangibles of a like nature, whether registered or unregistered, and with respect to any and all of the foregoing: (i) all registrations and applications for registration thereof including, without limitation, the registrations and applications listed in Schedule A attached hereto, (ii) all extension and renewals thereof, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) all rights to sue or otherwise recover for any past, present and future infringement, dilution, or other violation thereof, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit now or hereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively “Trademarks”); and

(b) all agreements, licenses and covenants pursuant to which such Grantor has been granted rights in any Trademark or has otherwise been granted or has granted a covenant not to sue for infringement or other violation of any Trademark, including, without limitation, each agreement listed in Schedule A attached hereto.

SECTION 2.2 Certain Limited Exclusions. Notwithstanding anything herein to the contrary, in no event shall the Trademark Collateral include or the security interest granted under Section 2.1 hereof attach to any “intent-to-use” application for registration of a Trademark filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, prior to the filing of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, solely to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law.

SECTION 3. Security Agreement

The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the Secured Parties pursuant to the Guarantee and Collateral Agreement, and the Grantors hereby acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guarantee and Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Agreement is deemed to conflict with the Guarantee and Collateral Agreement, the provisions of the Guarantee and Collateral Agreement shall control.

SECTION 4. Governing Law

THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICTS OF LAW RULES THAT WOULD RESULT IN THE APPLICATION OF A DIFFERENT GOVERNING LAW (OTHER THAN ANY MANDATORY

PROVISIONS OF THE UCC RELATING TO THE LAW GOVERNING PERFECTION AND EFFECT OF PERFECTION OF THE SECURITY INTERESTS).

SECTION 5. Counterparts; Electronic Signature.

This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by facsimile or other electronic imaging means), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Agreement by facsimile or other electronic transmission (e.g. "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart hereof.

SECTION 6. Collateral Agent.

The Collateral Agent shall be entitled to the same rights, protections, immunities and indemnities as set forth in the Credit Agreement, as if the provisions setting forth those rights, protections, immunities and indemnities are fully set forth herein.

[Remainder of page intentionally left blank]


IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above

**ANDELYN BIOSCIENCES, INC.,
as Grantor**


DocuSigned by:
By: Adam Lauber
ABA76CE509074DC
Name: Adam Lauber
Title: Chief Financial Officer

Accepted and Agreed:

ALTER DOMUS (US) LLC,
solely in its capacity as Collateral Agent
and not in its individual capacity

By: 
Name: Matthew Trybula
Title: Associate Counsel

SCHEDULE A
to
FIRST SUPPLEMENTAL TRADEMARK SECURITY AGREEMENT
TRADEMARK REGISTRATIONS AND APPLICATIONS

Registration Number	Serial Number	Mark	Jurisdiction	Owner	Registration Date / Application Date
7,083,888	97288838		United States	Andelyn Biosciences	Application Date: 01-Mar-2022 Registration Date: 20-Jun-2023
7014451	97644428	DIGITAL CDMO	United States	Andelyn Biosciences	Application Date: 24-Oct-2022 Registration Date: 28-Mar-2023
7084156	97345667	PIONEERING SOLUTIONS THAT TURN HOPE INTO REALITY	United States	Andelyn Biosciences	Application Date: 04-Apr-2022 Registration Date: 20-Jun-2023

DOMAIN NAMES

Domain Name	Registrar	Registrant/Registrant Organization	Expiration Date
andelyntest.dev	Directnic	Bryan Holmes/Andelyn Biosciences	05-21-2024
thedigitalcdmo.com	Directnic	Bryan Holmes/Andelyn Biosciences	12-16-2024
digitalcdmo.com	Directnic	Bryan Holmes/Andelyn Biosciences	12-16-2024